56447-12-2

Usage

Uses

Used in Pharmaceutical Research:
2-cyanocyclopropane-1-carboxylic acid is used as a key intermediate in the development of novel pharmaceutical compounds for the treatment of various diseases and conditions, such as cancer and diabetes. Its unique structure and reactivity allow for the creation of innovative drug candidates with potential therapeutic benefits.
Used in Organic Synthesis:
In the field of organic synthesis, 2-cyanocyclopropane-1-carboxylic acid serves as a valuable building block for the synthesis of complex organic molecules and compounds. Its presence in these reactions can lead to the formation of new chemical entities with diverse applications in various industries.
Used in Laboratory Settings:
Due to its instability and reactivity, 2-cyanocyclopropane-1-carboxylic acid is primarily used in controlled laboratory environments. Researchers must exercise strict precautions when handling and utilizing 2-cyanocyclopropane-1-carboxylic acid to ensure safety and prevent unwanted reactions.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 107-13-1 acrylonitrile 
• 56447-11-1 2-cyano-1-cyclopropanecarboxylic acid ethyl ester 
• 3999-56-2 trans-racemic ethyl 2-cyanocyclopropane-1-carboxylate 
• 171055-07-5 Cyclopropan-dicarbonsaeure-(1,2)-2-methylester-1-nitril 

Downstream Products

• 171055-08-6 1-cyano-{2-[4-(2,3,4-trimethoxybenzyl)piperazin-1-yl]carbonyl}cyclopropane 

Relevant academic research and scientific papers

Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1

Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold. We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compounds. One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.

AMINOPYRIMIDINYL COMPOUNDS

A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C═O, —SO2—, —(C═O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.; A′ is selected from the group consisting of a bond, C═O, —SO2—, —(C═O)NR0′, —NR0′(C═O)—, and —(CRa′Rb′)q—, where R0′ is H or C1-C4 alkyl, and Ra′ and Rb′ are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, heteroaryl(C1-C6 alkyl), and heterocyclic(C1-C6 alkyl); Z is —(CH2)h— or a bond, where one or more methylene units are optionally substituted by one or more C1-C3 alkyl, CN, OH, methoxy, or halo, and where said alkyl may be substituted by one or more fluorine atoms; R1 and R1′ are independently selected from the group consisting of hydrogen, deuterium, C1-C4 alkyl, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, etc., wherein said alkyl, aryl, cycloalkyl, heterocyclic, or heteroaryl is further optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, halo, CN, C1-C4 alkylamino, C3-C6 cycloalkyl, etc.; R2 is selected from the group consisting of hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, halo, and cyano, where said alkyl may be substituted by one or more fluorine atoms; R3 is selected from the group consisting of hydrogen, deuterium, and amino; R4 is monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl wherein said aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, heterocycloalkyl, halo, C3-C6 cycloalkyl, etc., where said alkyl, cycloalkyl, alkoxy, or heterocycloalkyl may be substituted by one or more C1-C6 alkyl, halo, CN, OH, alkoxy, amino, —CO2H, —(CO)NH2, —(CO)NH(C1-C6 alkyl), or —(CO)N(C1-C6 alkyl)2, and where said alkyl may be further substituted by one or more fluorine atoms; R5 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, and hydroxyl; h is 1, 2 or 3; j and k are independently 0, 1, 2, or 3; m and n are independently 0, 1 or 2; and, q is 0, 1 or 2. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES

This disclosure relates to specific polyamine analogs and methods of treating cancer using polyamine analogs. The polyamine analogs have cyclopropyl groups in their internal segments.

Substituted sulfonamides

The compounds are N-(2,3,4-trimethoxybenzyl)piperazines N'-substituted by a radical containing a sulfonamide group, and pharmaceutically tolerable salts thereof, useful for treating myocardial ischaemic pathologies, cerebral vascular accident and manifest

Purine derivatives

Purines and pyrimidines having a fused cyclopropane ring in the side chain and the heterocyclic isosteres of said purines and pyrimidines have antiviral activity, especially against viruses of the herpes class.

2-Aminomethylcyclopropyl-1,1-dialkylacetals

3-azabicyclo(3.1.0)hexane-2-carboxylic acid, a plant gametocide, is prepared by effecting reaction between cis 2-aminomethylcyclopropyl-1,1-dimethyl acetal and a cyanide in the presence of a liquid lower-alkanecarboxylic acid; treating the resulting N-alkanoyl-3-azabicyclo(2.1.0)hexane-2-carbonitrile with a strong acid; treating the resulting 3-alkanoyl-3-azabicyclo(3.1.0)hexane-2-carboxylic acid with strong acid to form the desired 3-azabicyclo(3.1.0)hexane-2-carboxylic acid.

6-(Substituted-cycloalkylcarboxamide) penicillanic acids

Penicillins of the formula SPC1 Or a pharmaceutically-acceptable, nontoxic salt thereof, Wherein R1 and R2 are the same or different and each is hydrogen, fluorine, chlorine or bromine; or when R2 is hydrogen, R1 can also be cyano, hydroxyl, azido, amino or nitro; or R1 and R2 are bonded to a ring carbon atom and constitute a single oxygen atom; R3 is hydrogen, methyl, chlorine, bromine, cyano, methoxy or carboxyl; and n is 2 to 7; Are useful for their antibacterial activity.